News

Clinical trial results show that Zepatier (elbasvir/grazoprevir) is highly effective against hepatitis C virus (HCV) infection in sickle cell disease patients and others with inherited blood disorders. The study with these findings, “Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study,” was published in the journal…

Intensifying treatment with hydroxyurea in young children with sickle cell anemia is safe and improves several disease parameters in the long run, researchers demonstrated in a clinical trial (NCT00305175) comparing toddlers with older children. Based on the positive findings, researchers argue that the practice of giving small children higher…

The Bristol-Myers Squibb Foundation, Texas Children’s Cancer and Hematology Centers and Baylor College of Medicine plan to jointly create a treatment network for children with cancer and blood diseases in three sub-Saharan African countries. The $100 million initiative, Global HOPE (Hematology-Oncology Pediatric Excellence), aims to build the medical capacity needed to diagnose and properly…

Modus Therapeutics, a company developing treatments specifically for sickle cell disease, has successfully completed a financing campaign that raised a total of 32 million Swedish krona (about €3.4 million euros) to develop sevuparin. Sevuparin is a proprietary polysaccharide drug with the potential to restore blood flow and prevent…

Researchers in Alicante, Spain, established levels of normality for hemoglobin A in newborn screening by taking into account factors such as the babies being born prematurely and their mothers having immigrated from an area of the world where the prevalence of genetics mutations causing defects in the hemoglobin gene is high.